CD Markers
CD38


Topic Completed: 18 May 2020

Minor changes: 19 August 2020

Copyright: 2002-2020, PathologyOutlines.com, Inc.

PubMed Search: CD38[title] stain

Frido Bruehl, M.D.
Christian M. Schürch, M.D., Ph.D.
Page views in 2019: 4,541
Page views in 2020 to date: 4,839
Cite this page: Bruehl F, Schürch CM. CD38. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/cdmarkerscd38.html. Accessed October 28th, 2020.
Definition / general
  • Marker of cellular activation expressed by plasma cells, T cells, NK cells and other hematopoietic cell types during various stages of maturation
Essential features
  • Marker of activation and present on many hematopoietic cells, especially plasma cells
  • Used clinically as a prognostic marker in CLL as evaluated by flow cytometry
  • CD38 expression in lymphoid neoplasms is not specific for any discrete disease entity
  • Can be aberrantly expressed in carcinoma and melanoma
  • Absence of CD38 (in conjunction with CD34 positivity) is used as a marker for bone marrow hematopoietic stem cells
Terminology
Pathophysiology
Clinical features
Interpretation
  • CD38 expression is considered positive when the cell membrane shows strong and diffuse staining; the cytoplasm and nucleus should not stain with CD38 (Blood 2008;111:5173)
  • Few studies have reported on the use and interpretation of anti-CD38 antibodies in tissue sections for diagnostic purposes; interpretation is difficult due to the prevalence of CD38 in many cell types and the necessity for quantitative assessment more amenable to flow cytometric studies (Am J Surg Pathol 2006;30:585)
Uses by pathologists
  • Flow cytometry is the primary use of anti-CD38 antibodies in the pathology laboratory
  • There is considerable confusion in the literature regarding CD38 and the unrelated antibody VS38 which targets the p63 antigen and is also used for detection of plasma cells in tissue sections and flow cytometry (Blood Cancer J 2018;8:117)
Prognostic factors
  • Chronic lymphocytic leukemia with CD38 expression is associated with a more aggressive clinical course and shorter overall survival (J Clin Pathol 2002;55:180, Br J Haematol 2003;120:1017)
  • Hairy cell leukemia with CD38 expression is associated with a more aggressive clinical course (Cancer Res 2015;75:3902)
  • Acute myeloid leukemia with CD38 expression was shown to be associated with a favorable prognosis and high numbers of immature CD34+ / CD38- blasts in myeloid leukemia are associated with unfavorable prognosis (Leuk Res 2000;24:153, Leukemia 2019;33:1102)
  • CD38 expression on multiple myeloma cells has been correlated to anti-CD38 treatment response (Blood 2016;128:959)
    • In the future, CD38 expression in tissue sections could be used to monitor anti-CD38 therapy with (bispecific) antibodies for early detection of treatment resistance (loss of CD38 expression)
Microscopic (histologic) description
  • Plasmacytoma: see images below
Microscopic (histologic) images

Contributed by Frido Bruehl, M.D.

Plasmacytoma

Plasmacytoma, CD38

Positive staining - normal
Positive staining - disease
Negative staining
  • Absence of CD38 expression does not reliably exclude a given pathologic diagnosis based on currently available data
  • CD38 surface expression may be reduced on multiple myeloma / plasma cells due to CD38 internalization induced by treatment with anti-CD38 antibodies (e.g. daratumumab) (Oncoimmunology 2018;7:e1486948)
  • CD38 has been used in conjunction with CD117 in fluorescence activated cell sorting of mast cells from bone marrow samples (CD117 positive and CD38 negative cells) (Am J Pathol 1996;149:1493)
Flow cytometry images

Contributed by Frido Bruehl, M.D.

CD38 positive CLL

CD38 negative CLL

Plasma cell neoplasm, CD38 versus CD45

Plasma cell neoplasm, CD38 versus CD138

Plasma cell neoplasm, CD38 versus CD19

Sample pathology report
  • Bone lesion, needle core biopsy:
    • Monotypic kappa expressing plasma cell neoplasm, consistent with plasmacytoma (see comment)
    • Comment: The needle core biopsy demonstrates a dense infiltration by a clonal plasma cell population with kappa light chain restriction. The neoplastic plasma cells are positive for CD38, CD138 and CD79a. Lambda light chains, CD20 and CD43 are not expressed. There are only scattered CD3 positive T cells. There is no amyloid deposition. In summary, the bone lesions represents a plasmacytoma; clinical, serological and imaging correlation is required.
Board review style question #1

Which of the following immunohistochemical markers has the lowest sensitivity for plasma cell neoplasms?

  1. CD38
  2. CD138
  3. CD20
  4. IgM
  5. VS38c
Board review answer #1
D. IgM is the best answer. IgM secreting plasma cell neoplasms are exceedingly rare, meanwhile CD20 is expressed in up to 20% of plasma cell neoplasms (Am J Hematol 2010;85:853).

Reference: CD38

Comment Here
Back to top
Image 01 Image 02